Natural products have been a rich source in providing leads for the development of drugs for
the treatment of bacterial infections. However, beyond the discovery of the natural product, …

In the late 1960s, the medical need for new antibiotics began to be questioned, and the
pharmaceutical industry shifted its emphasis of antibacterials from that of a therapeutic leader to …

Bacteria are continually bombarded by a multitude of chemicals from their environment, some
of which may serve as potential sources of carbon, nitrogen, and energy, while others may …

The prototypic oncogene c-MYC encodes a transcription factor that can drive proliferation
by promoting cell-cycle reentry. However, the mechanisms through which c-MYC achieves …

Condensing enzymes are essential in type II fatty acid synthesis and are promising targets
for antibacterial drug discovery. Recently, a new approach using a xylose-inducible plasmid …

Artifacts can seriously degrade the quality of computed tomographic (CT) images, sometimes
to the point of making them diagnostically unusable. To optimize image quality, it is …

A new class of inhibitors of the two-component regulatory systems (TCS) of bacteria was
discovered based on the salicylanilide screening hits, closantel (1) and tetrachlorosalicylanilide …

Fifty years of making analogs based on less than ten antibacterial scaffolds has resulted in
the development and marketing of over 100 antibacterial agents but, with the exception of the …

Type II fatty acid synthesis (FASII) is essential to bacterial cell viability and is a promising
target for the development of novel antibiotics. In the past decade, a few inhibitors have been …

Arsenic is effective in the treatment of acute promyelocytic leukemia. Paradoxically, it is also
carcinogenic. In the process of elucidating a mechanism of arsenic resistance in a leukemia …